US2021053922A1PendingUtilityA1
18f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
Est. expirySep 30, 2035(~9.2 yrs left)· nominal 20-yr term from priority
Inventors:Jens CardinaleMartin SchaeferKlaus KopkaMatthias EderUlrike Bauder-WuestMichael EisenhutMartina BenesovaUwe HaberkornFrederik Giesel
G01N 33/57555C07K 7/02G01N 33/68A61K 38/03A61K 31/465C07D 213/61C07B 59/002A61K 51/0455A61P 35/00A61K 51/04A61K 38/00C07B 2200/05G01N 33/57434
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
Claims
exact text as granted — not AI-modified1 . A precursor or a solvate of the compound of Formula I:
with:
i, j
0, 1
m
1-5
n
0-3
R
H, CH 3
AS
Natural or non-natural amino acid,
Z:
—CO 2 H, —SO 2 H, —SO 3 H, —SO 4 H, —PO 2 H,
—PO 3 H, —PO 4 H 2
X:
Naphthyl, Phenyl, Biphenyl, Indolyl, Benzothiazolyl,
Quinoyl
Y:
Aryl, Alkylaryl, Cyclopentyl, Cyclohexyl, Cycloheptyl,
N-Piperidyl and N-methylated Piperidyl salt
18 F-Tag:
With:
x = 1-5
Carbohydrate:
R 1 : Any alkyl, aryl or arylalkyl linker
R 2 : Any alkyl or aryl group
R 1 : Any alkyl, aryl or arylalkyl linker
R 2 : Any alkyl or aryl group
R 1 : Any alkyl, aryl or arylalkyl linker
R 2 : Any alkyl or aryl group
R 1 : Any alkyl, aryl or arylalkyl linker
R 2 : Any alkyl or aryl group
R 1 : Any alkyl, aryl or arylalkyl linker
R 2 : Any alkyl or aryl group
R 1 : Any alkyl, aryl or arylalkyl linker
R 2 : Any alkyl or aryl group
R 1 : Any alkyl, aryl or arylalkyl linker
R 2 : Any alkyl, or aryl group.
2 . The precursor or the solvate of claim 1 , wherein the compound has the structure:
wherein the linker A is selected from the group consisting of:
wherein R 1 =(Glu)-(Urea)-(Lys) and R 2 =(Linker B) m - 18 F Tag, m=1-5,
and linker B is selected from the group consisting of:
3 . The precursor or the solvate of claim 1 , wherein the compound is selected from the following
4 . The precursor or the solvate of claim 1 , wherein the non-natural amino acid has the formula
and R′=H, CO 2 H, CH 2 CO 2 H, C 2 H 4 CO 2 H, CH(CO 2 H) 2 , CH(CH 2 CO 2 H) 2 , CH(CO 2 H)(CH 2 CO 2 H), CH 2 CH(CO 2 H) 2 , SO 3 H;
o=1-3; R=H, CH 3 .
5 . The precursor or the solvate of claim 1 , wherein R 1 is selected from the group consisting of: methyl, 2-ethyl, 3-propyl, 2-,3-,4-phenyl, 2-,3-,4-phenylmethyl, and 2,3-,4-phenylpropyl.
6 . The precursor or the solvate of claim 1 , wherein R 2 is selected from the group consisting of methyl, isopropyl, tert-butyl, phenyl, and 1-naphtyl.
7 . A pharmaceutical composition comprising the precursor or the solvate of claim 1 , and a pharmaceutically acceptable carrier.
8 . A method of imaging a prostate region in a patient comprising the steps of:
(i) administering to a patient a diagnostically effective amount of the precursor or the solvate of claim 1 , (ii) exposing the prostate region of the patient to a scanning device to detect the 18F-tag; and (iii) obtaining an image of the prostate region of the patient by the scanning device.Join the waitlist — get patent alerts
Track US2021053922A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.